Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Maxcyte (MXCT) Shares Outstanding (Weighted Average) (2019 - 2026)

Maxcyte has reported Shares Outstanding (Weighted Average) over the past 7 years, most recently at $106.4 million for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 1.51% to $106.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $106.4 million through Dec 2025, up 1.51% year-over-year, with the annual reading at $106.4 million for FY2025, 1.51% up from the prior year.
  • Shares Outstanding (Weighted Average) was $106.4 million for Q4 2025 at Maxcyte, roughly flat from $106.3 million in the prior quarter.
  • Over five years, Shares Outstanding (Weighted Average) peaked at $106.4 million in Q4 2025 and troughed at $82.9 million in Q2 2021.
  • The 5-year median for Shares Outstanding (Weighted Average) is $103.3 million (2023), against an average of $101.2 million.
  • Year-over-year, Shares Outstanding (Weighted Average) skyrocketed 34.48% in 2021 and then rose 1.13% in 2024.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $90.6 million in 2021, then increased by 12.23% to $101.7 million in 2022, then increased by 1.54% to $103.3 million in 2023, then grew by 1.53% to $104.8 million in 2024, then rose by 1.51% to $106.4 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Shares Outstanding (Weighted Average) are $106.4 million (Q4 2025), $106.3 million (Q3 2025), and $106.2 million (Q2 2025).